Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

AZD2171 for refractory breast cancer: a phase 2 trial

AZD2171 for refractory breast cancer: a phase 2 trial. Breast Cancer Res Treat. 2007; 106(Suppl 1):Abstract 6080.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.